Last reviewed · How we verify
NVC-422 Solution, 0.3%
At a glance
| Generic name | NVC-422 Solution, 0.3% |
|---|---|
| Also known as | Auriclosene |
| Sponsor | NovaBay Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis (PHASE2)
- Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NVC-422 Solution, 0.3% CI brief — competitive landscape report
- NVC-422 Solution, 0.3% updates RSS · CI watch RSS
- NovaBay Pharmaceuticals, Inc. portfolio CI